Global experience and progress in GreenLight-XPS 180-Watt photoselective vaporization of the prostate
- PMID: 35499590
- PMCID: PMC9166849
- DOI: 10.1007/s00345-022-03997-2
Global experience and progress in GreenLight-XPS 180-Watt photoselective vaporization of the prostate
Abstract
Purpose: To evaluate changes in global perioperative data of GreenLight-XPS 180-Watt photo-selective vaporization of the prostate (GL-XPS) of the Global Greenlight Group (GGG) database.
Methods: 3441 men, who underwent GL-XPS for symptomatic BPH between 2011 and 2019 at seven high volume international centers, were included. Primary outcome measurements were operative time (OT; min), effective laser time (LT; min of OT), as well as intraoperative and postoperative adverse events (AEs), all analyzed by year of surgery (2011-2019) and prostate volume (PV) group (< 80 ml vs. 80-150 ml vs. > 150 ml).
Results: The median age was 70 years (interquartile range 64-77), the median PV was 64 ml (IQR 47-90). The OT and LT slightly increased but stayed highly efficient all in all. Median OT was 60 min (IQR 45-83) and LT was 33 min (IQR 23-46). Median energy use was 253 kJ (IQR 170-375) with an energy density of 3.94 kJ/ml (IQR 2.94-5.02). The relative probability of perioperative AEs decreased by 17% each year (p < 0.001). The relative probability of perioperative transfusion dropped significantly from 2% in 2011 to 0% in 2019 (p = 0.007). The early postoperative complications (within 30 days after surgery) decreased significantly from 48.8% (n = 106) in 2011 to 24.7% (n = 20) in 2019 (p > 0.001).
Conclusion: These findings from the GGG demonstrate significant improvement secondary to growing experience with GL-XPS between 2011 and 2019 in intraoperative AEs, including transfusions, and postoperative AEs. While staying highly efficient in OT and LT of GL-XPS within a 9-year period of experience.
Keywords: BPH; GL-XPS; Global Greenlight Group; Global experience; Greenlight.
© 2022. The Author(s).
Conflict of interest statement
Hannes Cash, Kevin Zorn, Dean Elterman, Edgardo F. Becher, Giovanni Ferrari and Luca Cindolo report receiving honoraria as consultant/proctor for Boston Scientific. All other authors report no conflict of interest.
Figures
References
-
- Foster HE, Barry MJ, Dahm P et al (2018) Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol 200(3):612–619. https://www.ncbi.nlm.nih.gov/pubmed/29775639 - PubMed
-
- Valdivieso R, Hueber PA, Meskawi M et al (2018) Multicentre international experience of 532-nm laser photoselective vaporization with GreenLight XPS in men with very large prostates. BJU Int 122(5):873–878. https://www.ncbi.nlm.nih.gov/pubmed/29570929 - PubMed
-
- Stone BV, Chughtai B, Forde JC et al (2016) Safety and Efficacy of GreenLight XPS laser vapoenucleation in prostates measuring over 150 mL. J Endourol 30(8):906–912. https://www.ncbi.nlm.nih.gov/pubmed/27203515 - PubMed
-
- Nickel JC, Aaron L, Barkin J et al (2018) Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J 12(10):303–312. https://www.ncbi.nlm.nih.gov/pubmed/30332601 - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
